Abstract. Systemic immune defects that are associated with disease progression exist in a variety of malignancies. γδ T cells are innate-like lymphocytes that do not require self-major histocompatibility complex-restricted priming. Ex vivo-expanded circulating γδ T cells exhibit promising antitumor activity and are a potential candidate for the treatment of various malignancies, including non-small cell lung cancer (NSCLC). In the present study, flow cytometry was used as a method to study the phenotypes and characteristics of γδ T cells. A lower frequency of circulating γδ T cells was observed in NSCLC patients than in healthy controls. In advanced NSCLC patients, γδ T cells were also detected in the pleural effusion, but the frequency of γδ T cells here was significantly lower than in the peripheral blood. Vδ1 phenotype, according to the fluorescence intensity of CD3 and γδTCR using flow cytometry. Finally, the present study reported a decrease in the expression of CD27 and CD28 molecules on the surface of circulating γδ T cells in NSCLC. The present data suggest the existence of a dysregulated repertoire of γδ T cells in NSCLC, which exhibit impaired activation and a reformed cytokine-releasing profile. Although the ex vivo expansion of γδ T cells may be a prospective therapeutic strategy in NSCLC patients, it remains necessary to clarify which subsets (Vδ1 or Vδ2) should be expanded and the sources from which γδ T cells should be generated.
Introduction
Unlike αβT cells, γδ T cells represent a minor subset of T cells that does not require self-majorhistocompatibility complex (MHC)-restricted priming (1) . γδ T cells are believed to serve as a bridge, connecting the innate and adaptive immune responses (1) . Following infection by microbial pathogens, γδ T cells appear to be the first T cells tomigrateto the lung (2) . Previous studies have identified that γδ T cells can mediate antitumor activity (3) . In humans, γδ T cells are primarily identified by the V(D)J recombination of the γ and δ chain genes, particularly their Vδ chain usage (4). Vδ2 cells (mainly Vγ9/Vδ2 cells) are the predominant γδ T-cell subset (50-75%) in the peripheral blood (PB) of healthy individuals (5) . Uniquely, this subset of γδ T cells responds to phosphoantigens via polymorphic γδ T-cell antigen receptors (TCR) and undergoes rapid activation (6, 7) . Owing to the relative abundance in the PB and ease of expansion, Vγ9/Vδ2 T-cell-based adoptive immunotherapy has been intensively investigated as the treatment for a variety of malignancies (8) (9) (10) . Vδ1 T cells represent <30% of γδ T cells in the PB, but have been identified as an enriched subset in the thymus and in epithelial tissues, including the dermis, gut epithelium and spleen (11) . Unlike Vδ2 cells, Vδ1 cells do not respond to phosphoantigens, but are able to recognize the MHC class I chain-related molecules A and B (12) . A recent study suggested that Vδ1 + T cells derived from the PB of normal donors are able to undergo ex vivo expansion by administration of phytohemagglutinin (PHA) and interleukin-7 (IL-7) (13); moreover, Vδ1 T cells exhibit more favorable antitumor activity than Vδ2 T cells in colon cancer (13) . Ex vivo-expanded circulating γδ T cells represent a promising prospect in antitumor activities and are a potential candidate treatment for various malignancies, including non-small cell lung cancer (NSCLC). A phase I clinical study is currently being conducted using adoptive γδ T cell therapy in patients with advanced or recurrent NSCLC (14) . However, the characterization of γδ T cells remains poorly understood in advanced NSCLC.
In the present study, the absolute count of lymphocytes and monocytes, and the subtypes and characteristics of γδ T cells in the PB and pleural effusion of advanced NSCLC patients were analyzed in order to investigate which subsets (Vδ1 or Vδ2) should be expanded ex vivo and used as the source from
Characterization of γδ T cells in patients
with non-small cell lung cancer which these γδ T cells should be generated for adoptive γδ T cell therapy. Statistical analysis. Data are presented as the mean ± standard error of the mean. Comparisons between groups were made using an unpaired Student's t-test. P-values <0.05 were considered to indicate statistical significance. GraphPad Prism version 5 (GraphPad Software, Inc., La Jolla, CA, USA) was used for all statistical calculation and figure generation.
Materials and methods

Subject
Results
Absolute number of lymphocytes and monocytes in the PB of NSCLC patients.
The complete blood cell counts of 102 patients (51 male, 51 female; 64.45±1.55 years) with stage I-IV NSCLC were retrospectively analyzed. The clinicopathological features of patients are provided in Table I . The blood cell count data were obtained from 114 cases of aged-matched healthy controls (51 male, 63 female; mean age, 63.40±1.1 years). The absolute number of lymphocytes and monocytes was assessed using an automatic hematology analyzer. The absolute value of lymphocytes (normal range, 1.10-3.20x10 9 /l) in the PB was 1.285x10 9 ±0.049x10 9 /l in the NSCLC group, significantly lower than that of the healthy controls, where it was 2.065x10 9 ±0.051x10 9 /l (P<0.001) (Fig. 1A) ; however, the absolute value of monocytes (normal range is 0.10-0.60x10 9 /l) was 0.484x10 9 ±0.022x10 9 /l in the NSCLC group, significantly higher than that in the healthy controls, where it was 0.363±0.011 (P<0.001) (Fig. 1B) . 
years)
. Among these subjects, 20 patients with NSCLC and 11 healthy donors were further analyzed for the percentage of Vδ1 and Vδ2 T cells, two major subsets of γδ T cells, and the expression of the co-stimulatory markersCD27 and CD28. To assess the frequency of γδ T cells present in the sample, lymphocytes were first gated on the basis of a forward scatter/side scatter (FSC/SSC) profile, followed by γδ T-cell analysis in a gated population with CD3 + staining ( Fig. 2A) . A pan-TCRγδ antibody was used to identify γδ T cells, and Vδ1/Vδ2 antibodies were further used to determine Vδ1 and Vδ2 subsets ( Fig. 2A) . Fig. 2B shows that in NSCLC patients, the mean frequency of CD3 + γδ + T cells was 4.16±0.44% (n=35), whereas the value in healthy individuals was 6.40±0.77% (n=25); the two groups have a statistically significant difference (P<0.05). In parallel with a previous report (16) , Vδ2 T cells represented a major subset, and the Vδ2/Vδ1 ratio was >1 in the PB of all normal donors (100.0%) (11/11); however, in NSCLC patients, the T cells was higher in the PB of the two groups (5.32±1.08%) than that in the pleural effusion of the two groups (2.47±0.69%), with a statistically significant difference (P<0.05) (Fig. 3A) .
In the 12 NSCLC patients recruited for the current experiment, the Vδ2 + γδ T cell was the predominant subtype in the PB in 5 patients (41.7%), whereas Vδ1 or Vδ1 -
Vδ2
-was the major CD3 + γδ + T cell subtype in the remaining 7 patients (58.3%). In the pleural effusion, Vδ1 or Vδ1 -
-was the predominant subtype of CD3 + γδ T cells in all 12 patients (100.0%). In comparison to the frequency of Vδ1 + and Vδ2 + T cells between the PB and the pleural effusion, data from the present study showed that the percentage of Vδ2 T cells was significant lower in the pleural effusion, with 36.01±8.25% of cells found to be T cells in the PB vs. 8.16±2.38% in the pleural effusion (P<0.01) (Fig. 3B) . However, the percentage of Vδ1 T cells in the pleural effusion was significantly higher, with 44.54±8.49 of cells in the blood found to be T cells vs. 64.78±5.50% in the pleural effusion (P<0.05) (Fig. 3C ).
Vδ1 and Vδ2 have different mean fluorescence intensity (MFI) for CD3 and TCR γδ.
Next, the expression of CD3 and TCRγδ on the surface of the Vδ1 and Vδ2 T-cell population was analyzed. During the study of circulating Vδ1 and Vδ2 cells in the 20 NSCLC patients and 11 healthy donors, further analysis was performed, investigating the MFI of CD3 in Vδ2 and Vδ1 γδ T cells. This analysis found that the MFI of CD3 was significant higher in Vδ2 cells than in Vδ1 cells in NSCLC patients and healthy individuals; a CD3 MFI of 4,776±691.2 in Vδ2 + cells vs. 2,612±319.4 in Vδ1 + cells (n=20; P<0.01) was observed in NSCLC patients (Fig. 4A) , and a CD3 MFI 9,689±1,270 in Vδ2 + cells vs. 3,454±592.6 in Vδ1 + cells in healthy controls (n=11; P<0.001) (Fig. 4B ). The MFI of TCRγδ was significantly lower in Vδ2 + cells than in Vδ1 + cells in NSCLC (858±62.49 vs. 2,614±313.10, respectively; n=20; P<0.001) (Fig. 4C) , and in healthy controls (1,351±182.8 vs. 3,724±725.20, respectively; n=11; P<0.01) (Fig. 4D) 
CD8
+ T lymphocytes, as well as on γδ T cells (17) . CD27 and its ligand, CD70, are involved in a signaling pathway that promotes the survival of primed T cells (18) . CD28 is a well-documented co-receptor of αβT cells, and activation of the CD3/CD28 pathway will enhance the proliferation of αβT cells (19) . Therefore, the expression of CD27 and CD28 on the surface of γδ T cells was investigated in the PB of the same 20 NSCLC patients and 11 healthy donors. The gating strategy is shown in Fig. 5A . In brief, lymphocytes were first gated based on their FSC/SSC profile, followed by analysis of CD27/CD28 expression in a gated population of CD3 + γδ + cells (Fig. 5A ). There was a significantly increased frequency of CD27 -CD28 -CD3 + γδ + T cells in the PB of NSCLC patients (40.2±5.7%) compared with the PB of the healthy control group (11.9±4.8%) (P<0.01) (Fig. 5B ). An increased population of CD27 -CD28 -CD3 + γδ + T cells was also observed in the pleural effusion of NSCLC patients compared with that in the PB, but the difference was not statistically significant (data not shown).
Discussion
In the present study, decreased numbers of lymphocytes and increased numbers of monocytes were observed in the PB of NSCLC patients. This observation supports previous reports concerning the systemic immune defects that exist in malignancies, which include low numbers of circulating T cells and low chemokine levels, and enhance the number of anti-tumor T cells that are likely to partially reverse immunosuppressive activities (20) . A low lymphocyte-to-monocyte ratio (LMR) has been shown to be an independent unfavorable prognostic factor for predicting survival in SCLC patients (21) . A lower LMR most likely have decreased cytotoxic T lymphocytes and higher tumor-associated macrophages (22) . A previous study reported that the monocyte count in the peripheral blood was higher in the patients with cervical and endometrial cancer compared with a control group of healthy blood donors (23) . An elevated number of peripheral monocytes has also been associated with a poor prognosis for patients with lung adenocarcinoma (24). The number of γδ T cells is lower in elderly individuals than in the young population (25) . The present study also observed a decrease in the frequency of γδ T cells in the PB of NSCLC patients. Circulating Vδ2 γδ T cells appeared to lose their predominance in NSCLC patients compared with healthy individuals; Vδ1, and to a lesser extent Vδ1 -Vδ2 -γδ, T cells became a major subset and the ratio of Vδ2:Vδ1 T cells inverted in one-third of all studied patients; a similar observation has been reported in a study of γδ T cells in gastric cancer (26) . On the basis of previous studies, Vδ1 T cells are less susceptible to activation-induced cell death and exhaustion than Vδ2 T cells (27, 28) . Vδ1 T cells are also preferentially persistent in vivo; this could be the reason why Vδ1 T cells are predominant in the PB of patients with lung cancer.
In the present study, γδ T cells were also detected in the pleural effusion of patients with advanced NSCLC, in whom the frequency of Vδ2 + T cells was even lower than in the PB, and Vδ1 or Vδ1 subsets in all subjects studied. To the best of our knowledge, no previous study has reported on the characteristics of γδ T cells and their subsets in the pleural effusion of NSCLC. Tumor-infiltrating leukocytes (TILs) represent a wide range of variety of immune cells that have been found in invading solid tumors, and the extent of infiltration of γδ T cells is reported to enable a variety of prognostic predictions, for example; in the earlier stages of melanoma there are higher percentages of intra-tumoral γδ T cells, particularly V2γδ T cells, compared with advanced stage melanoma, which serves as a biomarker of good prognoses; in contrast, a higher level of intra-tumoral V1 γδ T cells has been reported as a poor prognostic factor in breast cancer (29, 30) . In a study of γδ T cells in the TILs of melanoma, γδ T cells were detected in 76% of tumor specimens using immunohistochemistry. Vδ1 was the major subset presenting in 52% of samples (31, 32) . In a study of γδ T cells in human colon cancer, it was found that the majority (80%) of IL-17 + γδ T cells expressed Vδ1 (γδ17), and those cells thatinfiltratedγδ17 T cells in the tumor were associated with advanced tumor grades and progression. As a result, these T cells may serve as prognostic markers in human colon cancer (33) . However, Peng et al (34) reported that the Vδ1 subtype was observed to be the dominant subtype among tumor infiltrating lymphocytes in a group of breast cancer patients, and that it appeared to exhibit a broad range of immune suppression activities, via suppressing the production of IL-2 by CD4 + and CD8 + T cells, and the maturation of dendritic cells. The present study indicates that γδ T cells derived from the pleural effusion could be a source of adoptive γδ T cell immunotherapy in lung cancer. Unlike for Vδ2 T cells, which respond to phosphoantigens, there is no protocol concerning the expansion of Vδ1 + populations ex vivo, although a recent study indicated that PHA and IL-7 may be candidates to facilitate expansion of the Vδ1 subtype in circulating γδ T cells (13) . However, the present authors have been unable to obtain a satisfactory result on the ex vivo expansion of Vδ1 or Vδ2 cells, either using PHA and IL-7 stimulation or zoledronic acid when using the γδ T cells isolated from pleural effusion in advanced NSCLC (Bao et al, unpublished data). This is likely to be due to the low frequency of γδ T cells in the pleural effusion, and the fact that the majority γδ T cells are Vδ1 T cells. Moreover, it remains unclear whether there are similar antitumor effects of Vδ1 T cells derived from PB or from pleural effusion in lung cancer patients.
In the present study, Vδ2 T cells appeared to be a population of γδ T cells with a CD3
bright TCRγδ dim phenotype; by contrast, Vδ1 T cells were characterized by a CD3 dim TCRγδ bright phenotype. A previous study suggested that TCRγδ-deficient mice display reduced tumor growth compared with wild-type animals (35) . The different levels of CD3 and TCRγδ expression may indicate that in these two subsets, a variety of co-stimulatory signaling pathways could be involved in the regulation of activation and proliferation.
The present study found a decrease in the expression of CD27 and CD28 molecules on the surface of circulating γδ T cells in NSCLC patients. A previous study showed a majority of Vδ2 cells in PB are CD27 + γδ T cells (36) . Another prior study reported evidence supporting an absolute requirement of CD27 for the expansion of γδ T cells by employing a CD27-deficient mice model. CD27 and its ligand CD70 are involved in a signaling pathway that is required to promote the survival of primed T cells (17, 37) . In the thymus of mice, CD27 is likely to regulate γδ T cell differentiation, and CD27 + γδ T cells produce interferon (IFN)-γ, whereas CD27 -γδ T cells produce IL-17 (38) . In αβ T cells, 'signal 1', which refers to the mature T cells recognizing and binding to a major histocompatibility complex (MHC) molecule carrying a peptide antigen through their antigen-specific receptors (TCR), together with a co-stimulatory pathway, CD28/B7, provides a 'second signal' that is required for the activation and proliferation of T cells (39); this CD28/B7 pathway involves the interaction of co-stimulatory molecule CD28 with its ligands B7-1 (CD80) and B7-2 (CD86) on the antigen presenting cells, and is critical for T-cell activation, proliferation, and survival (40) ; however, the requirement of the additional CD28/B7 signal for the activation of γδ T cells remains controversial (41) . In studying lymphocytes isolated from the lymph node, it was apparent that CD28 is expressed on the surface of γδ T cells and has the capability to promote the activation of γδ T cells, as well as their proliferation and survival, mainly by stimulating γδ T cells to produce and secrete IL-2 (42, 43) . Data obtained from a study of CD28-deficient mice suggested that the population of IFN-γ + and IL-17 + γδ T cells failed to expand during infection (43, 44) , indicating that CD28 co-stimulation is also necessary for γδ T cell expansion. Downregulation of CD27 and CD28 molecules in circulating γδ T cells in NSCLC patients suggests an impaired capacity to activate and proliferate γδ T cells in those patients, and indicates that they have a different cytokine profile to healthy individuals (42) .
The present data suggested the presence of a dysregulated repertoire of γδ T cells, including impaired activation and a reformed cytokine releasing profile of γδ T cells in NSCLC. Although the ex vivo expansion of γδ T cells may be a prospective therapeutic strategy in NSCLC patients, it remains necessary to clarify which subsets (Vδ1 or Vδ2) should be expanded and the sources from which these γδ T cells should be generated.
